IASLC Consensus Statement on Liquid Biopsy

Evolution in Treatment of Brain Metastases in Mutation-Driven Non-Small Cell Lung Cancer

Exploring the Potential of Immuno-oncology Combination Therapy

Q & A with Yi-Long Wu, MD

Adjuvant Gefitinib Extended Disease-Free Survival in Patients With Stage II/IIIA Non-Small Cell Lung Cancer With EGFR-Activating Mutations

Adjuvant Gefitinib Extended Disease-Free Survival in Patients With Stage II/IIIA Non-Small Cell Lung Cancer With EGFR-Activating Mutations

ADJUVANT Trial of Gefitinib Versus Chemotherapy in Resected EGFR-Mutations Non-Small Cell Lung Cancer

Mental Health Really Matters: Lung Cancer Diagnosis Has the Greatest Risk of Suicide among Cancer Patients in USA – SEER Database Analysis

Clinical Labeling in Medicinal Products: An Interview With Dr. David Planchard About the Effects of BRAF Mutations on Non-small Cell Lung Cancer Outcomes and Therapeutic Selection

IASLC Atlas of PD-L1 Immunohistochemistry Testing in Lung Cancer

IASLC Thoracic Oncology (2nd ed.)

The CRISPR-Cas9 Toolkit: Moving From Bench to Bedside